Cover Image
市場調查報告書

B型流行性感冒嗜血桿菌感染疾病:開發中產品分析

Haemophilus influenzae Type B Infections - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 255972
出版日期 內容資訊 英文 62 Pages
訂單完成後即時交付
價格
Back to Top
B型流行性感冒嗜血桿菌感染疾病:開發中產品分析 Haemophilus influenzae Type B Infections - Pipeline Review, H2 2016
出版日期: 2016年10月29日 內容資訊: 英文 62 Pages
簡介

本報告提供全球B型流行性感冒嗜血桿菌感染疾病治療藥的開發趨勢調查,提供您開發中產品的各開發階段比較分析,藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,這個部門的最新趨勢,主要企業的評估等。

簡介

  • 調查範圍

B型流行性感冒嗜血桿菌感染疾病概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

B型流行性感冒嗜血桿菌感染疾病:企業開發中的治療藥

B型流行性感冒嗜血桿菌感染疾病:大學/機關研究中的治療藥

B型流行性感冒嗜血桿菌感染疾病:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

B型流行性感冒嗜血桿菌感染疾病:企業開發中的產品

B型流行性感冒嗜血桿菌感染疾病:大學/機關研究中的產品

B型流行性感冒嗜血桿菌感染疾病的治療藥開發企業

  • Beijing Minhai Biotechnology Co., Ltd
  • Biological E. Limited
  • 第一三共
  • Indian Immunologicals Limited
  • LG Life Science LTD.
  • Panacea Biotec Limited
  • Sanofi Pasteur SA
  • Sinovac Biotech Ltd.
  • Zydus Cadila Healthcare Limited

B型流行性感冒嗜血桿菌感染疾病:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各給藥途徑
  • 各分子類型

藥物簡介

B型流行性感冒嗜血桿菌感染疾病:最近的開發平台趨勢

B型流行性感冒嗜血桿菌感染疾病:暫停中的計劃

B型流行性感冒嗜血桿菌感染疾病:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8617IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Haemophilus influenzae Type B Infections - Pipeline Review, H2 2016, provides an overview of the Haemophilus influenzae Type B Infections (Infectious Disease) pipeline landscape.

Haemophilus influenzae type B (Hib) is a bacterium that causes a life-threatening infection that can lead to serious illness, especially in children. Symptoms include severe headache, stiff neck, convulsions or seizures, severe drowsiness, difficulty waking up, loss of consciousness or difficulty with breathing. Predisposing factors include age and weakened immune system. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Haemophilus influenzae Type B Infections - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Haemophilus influenzae Type B Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Haemophilus influenzae Type B Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Haemophilus influenzae Type B Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 1, 4, 2, 3, 1 and 6 respectively for Similarly, the Universities portfolio in Discovery stages comprises 2 molecules, respectively for Haemophilus influenzae Type B Infections.

Haemophilus influenzae Type B Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Haemophilus influenzae Type B Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Haemophilus influenzae Type B Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Haemophilus influenzae Type B Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Haemophilus influenzae Type B Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Haemophilus influenzae Type B Infections (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Haemophilus influenzae Type B Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Haemophilus influenzae Type B Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Haemophilus influenzae Type B Infections Overview
  • Therapeutics Development
    • Pipeline Products for Haemophilus influenzae Type B Infections - Overview
    • Pipeline Products for Haemophilus influenzae Type B Infections - Comparative Analysis
  • Haemophilus influenzae Type B Infections - Therapeutics under Development by Companies
  • Haemophilus influenzae Type B Infections - Therapeutics under Investigation by Universities/Institutes
  • Haemophilus influenzae Type B Infections - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Haemophilus influenzae Type B Infections - Products under Development by Companies
  • Haemophilus influenzae Type B Infections - Products under Investigation by Universities/Institutes
  • Haemophilus influenzae Type B Infections - Companies Involved in Therapeutics Development
    • Beijing Minhai Biotechnology Co., Ltd
    • Biological E. Limited
    • Daiichi Sankyo Company, Limited
    • Indian Immunologicals Limited
    • Kaketsuken K.K.
    • LG Life Science LTD.
    • Panacea Biotec Limited
    • Sanofi Pasteur SA
    • Sinovac Biotech Ltd.
    • Zydus Cadila Healthcare Limited
  • Haemophilus influenzae Type B Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (wholl cell) + tetanus) (pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + haemophilus influenza [serotype B] + pertussis (acellular) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (7-valent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole-cell) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (Haemophilus influenzae [serotype B] + meningococcal [serotypes A, C]) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (meningococcal + Haemophilus influenzae [serotype B]) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Eupenta - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • haemophilus influenzae B vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Haemophilus influenzae B vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Haemophilus influenzae B vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hemophilus influenza [serotype B] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KD-370 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LT-Hib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NU-300 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VN-0105 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Haemophilus influenzae Type B Infections - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Haemophilus influenzae Type B Infections, H2 2016
  • Number of Products under Development for Haemophilus influenzae Type B Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Haemophilus influenzae Type B Infections - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2016
  • Haemophilus influenzae Type B Infections - Pipeline by Biological E. Limited, H2 2016
  • Haemophilus influenzae Type B Infections - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Haemophilus influenzae Type B Infections - Pipeline by Indian Immunologicals Limited, H2 2016
  • Haemophilus influenzae Type B Infections - Pipeline by Kaketsuken K.K., H2 2016
  • Haemophilus influenzae Type B Infections - Pipeline by LG Life Science LTD., H2 2016
  • Haemophilus influenzae Type B Infections - Pipeline by Panacea Biotec Limited, H2 2016
  • Haemophilus influenzae Type B Infections - Pipeline by Sanofi Pasteur SA, H2 2016
  • Haemophilus influenzae Type B Infections - Pipeline by Sinovac Biotech Ltd., H2 2016
  • Haemophilus influenzae Type B Infections - Pipeline by Zydus Cadila Healthcare Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Haemophilus influenzae Type B Infections - Dormant Projects, H2 2016
  • Haemophilus influenzae Type B Infections - Dormant Projects (Contd..1), H2 2016

List of Figures

  • Number of Products under Development for Haemophilus influenzae Type B Infections, H2 2016
  • Number of Products under Development for Haemophilus influenzae Type B Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top